Market revenue in 2023 | USD 1,637.8 million |
Market revenue in 2030 | USD 2,465.0 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.42% in 2023. Horizon Databook has segmented the South Africa active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
South Africa accounted for 29.3% of the MEA’s market in 2020. Various government initiatives, such as the development of special economic zones, Tripartite Free Trade Areas, tax breaks, and establishment of the South African Health Products Regulatory Authority (SAHPRA), are expected to increase foreign investments & collaborations, thereby boosting the market.
In January 2014, Novotech expanded its services in South Africa. South Africa is currently the most developed economy in Africa, owing to the availability of expertise in certain indications such as HIV.
The company has conducted several studies on HIV and tuberculosis with locally hired staff. Growing number of clinical trials in the country is projected to create opportunities for the active pharmaceutical ingredient CDMOs.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into South Africa active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account